New Form of Radioimmunotherapy for Kidney Cancer

by Sheela Philomena on  June 09, 2011 at 12:32 PM Cancer News
  •   Print
  •   Share
  •   Comments
  •  Text 
A novel form of radioimmunotherapy shows positive results in patients with progressive kidney cancer. The therapy slows the growth of kidney cancer cells.

"This study is another step forward in developing a cancer therapy that has the potential to provide additional treatment options for patients with renal cell carcinoma," says Wim Oyen, MD, professor and chairman of the department of nuclear medicine at Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. "In many cases we were able to stop the disease from progressing and hopefully prolong patient survival without compromising their quality of life with serious adverse effects."

According to the American Cancer Society, 50,000 Americans are diagnosed with kidney cancer each year. In adults, the most common type of kidney cancer is renal cell carcinoma.

Radioimmunotherapy is a treatment for cancer comprising medical radionuclides bound with antibodies that recognize physiological changes involved in the disease process. This specific therapy, called Lu-177-cG250, targets kidney tumors with the monoclonal antibody cG250, which recognizes carbonic anhydrase IX an antigen associated with renal cell carcinoma. Once inside the body the treatment targets cancerous tissues expressing this antigen, and the radionuclide kills those cells, sparing surrounding healthy tissues.

For the purposes of this study, 20 patients with progressive, metastasized renal cell carcinoma received a maximum of three doses of Lu-177-cG250 and were evaluated for toxicity and therapeutic efficacy in three-month increments. A majority of patients, 14 out of 20, were able to reach stabilization of their cancer 12 weeks after treatment. Tumor growth averages dropped from 28.5 percent increase in size before treatment to 4.1 percent during the three months after their first treatment cycle. This study shows that Lu-177-cG250 is highly effective for targeting tumor lesions and for reducing cancer proliferation in patients with progressive kidney cancer.

Source-Eurekalert

 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Medwonders Health Network

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
Quiz on Cancer
Looking for information on cancer? Go through medindia's Cancer quiz.
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
Kidney
Complete Medindia Resources
News Categories:  
Mental Health Center

Cancer Related News

» Cardio-Pulmonary Function can be a Strong Indicator for Survival Chances of Breast Cancer Patients » Post Surgery Will the Tumour Return? New Breast Cancer Test to Predict Exactly
» Scientists Develop Compound That Triggers Cancer Cell Death » Iraqi National Hopes to Find Affordable Treatment for His Cancer in India
» New Technique can Help Doctors Detect Pancreatic Cancer » Colorectal Cancer Risk Factors Probed
» Breast MRI 'Better Than Clinical Approach for Predicting Chemotherapy's Efficiency' » No Need for PSA-Based Screening for Prostate Cancer: Task Force
Read More >>